136 related articles for article (PubMed ID: 32350975)
1. Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial.
Zidan A; Hussaini S; Gibson S; Brooks G; Mejico L
Int J Clin Pract; 2020 Sep; 74(9):e13522. PubMed ID: 32350975
[TBL] [Abstract][Full Text] [Related]
2. Acupoint injection of onabotulinumtoxin A for migraines.
Hou M; Xie JF; Kong XP; Zhang Y; Shao YF; Wang C; Ren WT; Cui GF; Xin L; Hou YP
Toxins (Basel); 2015 Oct; 7(11):4442-54. PubMed ID: 26529014
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.
Zidan A; Roe C; Burke D; Mejico L
J Clin Neurosci; 2019 Nov; 69():237-240. PubMed ID: 31327585
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
6. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
[TBL] [Abstract][Full Text] [Related]
7. Effects of OnabotulintoxinA on Habituation of Laser Evoked Responses in Chronic Migraine.
de Tommaso M; Delussi M; Ricci K; Montemurno A; Carbone I; Vecchio E
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27231940
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
[TBL] [Abstract][Full Text] [Related]
9. Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis.
Shah S; Calderon MD; Wu W; Grant J; Rinehart J
J Child Neurol; 2018 Aug; 33(9):580-586. PubMed ID: 29877131
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Stark SR; Lucas SM; Christie SN; Degryse RE; Turkel CC;
Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic migraine with intramuscular pericranial injections of onabotulinumtoxin a.
Belvis R; Mas N
Recent Pat CNS Drug Discov; 2014; 9(3):181-92. PubMed ID: 25643127
[TBL] [Abstract][Full Text] [Related]
13. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Blumenfeld AM; Schim JD; Chippendale TJ
Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A in refractory chronic migraine: an open-label trial.
Menezes C; Rodrigues B; Magalhães E; Melo A
Arq Neuropsiquiatr; 2007 Sep; 65(3A):596-8. PubMed ID: 17876397
[TBL] [Abstract][Full Text] [Related]
17. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
18. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
[TBL] [Abstract][Full Text] [Related]
19. Regional Targeted Subcutaneous Injection of Botulinum Neurotoxin Type A in Refractory Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
Bono F; Mazza MR; Magro G; Spano G; Idone G; Laterza V; Tedeschi D; Pucci F; Gambardella A; Sarica A
Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235358
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine.
Cady RK; Saper J; Dexter K; Cady RJ; Manley HR
Headache; 2015 Apr; 55(4):529-42. PubMed ID: 25828648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
